Pfizer Corporation

Agouron Pharmaceuticals, Inc.

Pfizer Products Inc.

Eileen Valenzuela Tompkins

Yufeng Hong

Haitao Li

Mark Brian Anderson

Ved Prakash Pathak

Lance Christopher Christie

Min Teng

Jun Feng

Seiji Nukui

Hui Li

Chunfeng Yin

Iriny Botrous

Kevin Kun-Chin Liu

Ranjan Jagath Rajapakse

Eric T Sun

Vlad Edward Gregor

Anthony Lai Ling

Quyen-Quyen Thuy Do

Genevieve DeGuzman Paderes

James Faust

Haresh Vazir

Haresh N Vazir

David Robert Luthin

The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R, R, R, R, R, R, R, and Rare as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.

[object Object]

The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R, R, R, R, R, R, R, and Rare as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ. 

3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

Non-peptide GNRH agents, methods and intermediates for their preparation

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

Non-peptide GnRH agents, pharmaceutical compositions and methods for their use

There are disclosed novel neuropeptide Y ligands having the general formula IWherein the symbols W, A, D, R, R, R, Rare further defined in the description. Compounds of formula I are agonists and antagonists of neuropeptide Y, and are therefore useful as regulators.

Neuropeptide-Y ligands

Non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone are described. Such agents are useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated.

Non-peptide GnRH agents, Pharmaceutical compositions, and methods for their use

Growing community of inventors

Escondido, CA, United States of America

Eileen Valenzuela Tompkins